Haemonetics Short Term Investments vs Total Current Liabilities Analysis
HAE Stock | USD 85.55 0.12 0.14% |
Haemonetics financial indicator trend analysis is much more than just examining Haemonetics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Haemonetics is a good investment. Please check the relationship between Haemonetics Short Term Investments and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
Short Term Investments vs Total Current Liabilities
Short Term Investments vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Haemonetics Short Term Investments account and Total Current Liabilities. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Haemonetics' Short Term Investments and Total Current Liabilities is -0.49. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Haemonetics, assuming nothing else is changed. The correlation between historical values of Haemonetics' Short Term Investments and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Haemonetics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Short Term Investments i.e., Haemonetics' Short Term Investments and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | -0.49 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Short Term Investments
Short Term Investments is an item under the current assets section of Haemonetics balance sheet. It contains any investments Haemonetics undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Haemonetics can easily liquidate in the marketplace.Total Current Liabilities
Total Current Liabilities is an item on Haemonetics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Haemonetics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Haemonetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Haemonetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.At present, Haemonetics' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 25.70, whereas Selling General Administrative is forecasted to decline to about 235.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 505.5M | 615.1M | 676.5M | 710.4M | Total Revenue | 993.2M | 1.2B | 1.3B | 1.4B |
Haemonetics fundamental ratios Correlations
Click cells to compare fundamentals
Haemonetics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Haemonetics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 51.8M | 51.3M | 51.4M | 51.4M | 51.4M | 42.5M | |
Total Assets | 1.3B | 1.8B | 1.9B | 1.9B | 2.2B | 2.3B | |
Short Long Term Debt Total | 382.5M | 707.6M | 773.6M | 765.9M | 807.8M | 848.2M | |
Other Current Liab | 127.7M | 128.5M | 116.8M | 145.9M | 185.6M | 194.8M | |
Total Current Liabilities | 284.3M | 253.5M | 442.3M | 251.8M | 300.4M | 161.5M | |
Total Stockholder Equity | 587.1M | 731.7M | 749.4M | 818.0M | 960.0M | 535.9M | |
Property Plant And Equipment Net | 253.4M | 217.6M | 258.5M | 310.9M | 366.6M | 185.9M | |
Net Debt | 245.2M | 515.3M | 514.1M | 481.4M | 629.0M | 660.4M | |
Retained Earnings | 78.5M | 158.0M | 202.4M | 253.2M | 360.5M | 281.9M | |
Accounts Payable | 50.7M | 50.3M | 58.4M | 63.9M | 73.4M | 77.0M | |
Cash | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 138.4M | |
Non Current Assets Total | 663.5M | 1.1B | 1.1B | 1.2B | 1.4B | 1.5B | |
Non Currrent Assets Other | 66.3M | 76.9M | 63.2M | 107.0M | 90.5M | 99.5M | |
Cash And Short Term Investments | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 140.6M | |
Net Receivables | 165.2M | 127.6M | 159.4M | 179.1M | 206.6M | 120.7M | |
Liabilities And Stockholders Equity | 1.3B | 1.8B | 1.9B | 1.9B | 2.2B | 2.3B | |
Non Current Liabilities Total | 395.7M | 834.8M | 668.0M | 865.0M | 935.2M | 982.0M | |
Inventory | 270.3M | 322.6M | 293.0M | 259.4M | 317.2M | 333.1M | |
Other Current Assets | 30.8M | 102.1M | 88.3M | 46.7M | 66.3M | 40.1M | |
Other Stockholder Equity | 553.2M | 602.7M | 572.5M | 594.7M | 634.6M | 666.4M | |
Total Liab | 680.0M | 1.1B | 1.1B | 1.1B | 1.2B | 1.3B | |
Property Plant And Equipment Gross | 305.6M | 217.6M | 869.1M | 944.2M | 959.2M | 1.0B | |
Total Current Assets | 603.6M | 693.5M | 756.0M | 769.7M | 768.9M | 437.2M | |
Accumulated Other Comprehensive Income | (45.1M) | (29.5M) | (26.0M) | (30.4M) | (35.6M) | (37.4M) | |
Short Term Debt | 77.0M | 24.7M | 221.3M | 11.8M | 10.2M | 9.7M | |
Intangible Assets | 133.1M | 365.5M | 310.3M | 275.8M | 406.1M | 426.4M | |
Other Liab | 48.7M | 38.2M | 76.9M | 108.6M | 124.9M | 131.1M | |
Other Assets | 14.1M | 17.0M | 67.7M | 58.8M | 1.0 | 0.95 | |
Long Term Debt | 305.5M | 690.6M | 559.4M | 754.1M | 797.6M | 837.4M | |
Good Will | 210.7M | 466.4M | 467.3M | 466.2M | 565.1M | 593.3M | |
Property Plant Equipment | 253.4M | 277.4M | 258.5M | 310.9M | 357.5M | 213.6M | |
Current Deferred Revenue | 28.8M | 26.3M | 31.8M | 30.2M | 31.2M | 22.5M | |
Net Tangible Assets | 243.4M | (100.3M) | (28.1M) | 76.0M | 68.4M | 65.0M | |
Retained Earnings Total Equity | 78.5M | 158.0M | 202.4M | 253.2M | 227.9M | 230.9M | |
Long Term Debt Total | 305.5M | 690.6M | 559.4M | 754.1M | 867.2M | 910.6M | |
Capital Surpluse | 553.2M | 602.7M | 572.5M | 594.7M | 683.9M | 516.6M | |
Deferred Long Term Liab | 10.6M | 43.8M | 28.7M | 36.2M | 41.6M | 26.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.